More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
The St. Jude Promesa y Esperanza® (Promise and Hope), an initiative by St. Jude Children’s Research Hospital® and Univision Radio, the leading radio network serving Hispanic America, partner to increase awareness for national fundraiser against childhood cancer. As part of this partnership, Univision Radio will broadcast special programming on February 10 and 11 asking listeners to become Angeles de Esperanza (Angels of Hope) by making a donation of $20 per month, to find cures and save children.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65476-univision-radio-st-jude-children-s-research-hospital-national-fundraiser
Eagle Rare Kentucky Straight Bourbon Whiskey has named Angie Goodwin of Calhoun, Ky., as the winner of the Grand Prize 2014 Rare Life Award. Eagle Rare will donate $40,000 to Goodwin’s charity, Thumbs Up for Lane Goodwin Childhood Cancer Foundation, and host an awards ceremony in Henderson on March 7. Angie and her late son Lane started the foundation to support childhood cancer research through funding and advocacy and to assist families battling childhood cancer by providing education, financial assistance and a volunteer network.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64624-eagle-rare-bourbon-angie-goodwin-grand-prize-2014-rare-life-award
At 13 years old, Perry is a courageous three-time rare cancer survivor. Now she's fighting back for others like her. JOIN THE BATTLE. http://www.cycleforsurvival.org.
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
In recognition of Men’s Health Awareness Month and the start of summer, the American Academy of Dermatology (Academy) has released findings from a new survey, which found that more than 90% of American men know something about skin cancer, but only six in 10 (61%) know how to detect signs on their skin, and even fewer actually visit a doctor for annual skin cancer screenings (18%). These shortcomings were more apparent in younger men (18-34), who were also significantly less likely to believe that they are at risk for skin cancer than men over 35 (31% vs. 42%), and are more likely to protect their skin for cosmetic reasons than they are for health reasons (32% vs. 20%).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7074231-american-academy-of-dermatology-spot-me-skin-cancer-awareness/
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Susan G. Komen Knoxville readies the finish line for the 2014 Race for the Cure on October 18th at World’s Fair Park.
This year’s “Do You Tutu?” theme will attract a variety of pink tutus to the race. Komen Knoxville launched this theme to bring a sense of hope and happiness to the families, supporters and survivors battling breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7313552-komen-knoxville-laces-up-for-2014-race-for-the-cure-do-you-tutu/
